Seegene, Selventa team up for molecular diagnostics; Illumina names new general counsel;

 @FierceMedDev: CareFusion endures another Class I pump recall. News | Follow @FierceMedDev

 @MarkHFierce: Just attended our FierceBiotech breakfast and covered an R&D panel. Great ideas, but will they boost success rates? | Follow @MarkHFierce

 @DamianFierce: Roche Diagnostics is axing 170 jobs as its dissolves Applied Science biz. News | Follow @DamianFierce

> Alere ($ALR) is touting a new pilot study showing that at-home B-type natriuretic peptide tests are safe and effective for heart failure patients, providing information enabling personalized care. More

> Aspect Imaging won FDA clearance for its wrist imaging system, planning a summer rollout. Article

> French diagnostics outfit Theradiag won its third CE mark for an in vitro diagnostic kit for rheumatoid arthritis. News

> MBio Diagnostics has teamed up with the Foundation for Innovative New Diagnostics to develop a point-of-care tuberculosis assay, and Phase I results validate the pursuit, the company said. Item

> Seegene and Selventa are working together to develop new molecular diagnostics for autoimmune disorders, cancer and infectious diseases. Release

> In the wake of a costly lawsuit loss, Illumina ($ILMN) has appointed a new general counsel, hiring Charles Dadswell, who served a similar role at bioMérieux. More

Biotech News

 @FierceBiotech: E&Y: Biotech budget hawks rule the roost in year of mixed performance. Report | Follow @FierceBiotech

 @RyanMFierce: RBC analyst Michael Ye says BMS' PhII data for all-oral reg isn't much of a threat to Gilead. So, again, Gilead is still the frontrunner.  | Follow @RyanMFierce

> Chicago uses its turn in BIO spotlight to promote incubator plans. Story

> GlaxoSmithKline and Avalon Ventures forge $495M biotech startup alliance. News

> Moody's: Deep-pocketed pharma giants poised to boost M&A activity this year. More

Pharma News

 @FiercePharma: Novartis forges ahead with expansion at North Carolina vaccines campus, with $60M tech building. Report | Follow @FiercePharma

 @EricPFierce: $65 million DSM cell culture plant in Brisbane part of Australia's $345 million Translational Research Institute. Story | Follow @EricPFierce

> Thanks to Lexapro generics, Forest swings to loss on 32% drop in yearly sales. More

> Biogen MS pill soars onstage with impressive first-week script numbers. Article

> Drugmakers, get ready for bigger, faster dealmaking, Moody's says. Story

Pharma Manufacturing News

> Novartis expanding U.S. vaccine complex. Item

> U.S. lawmakers take another shot at mandating drug tracking system. More

> Fujifilm expands former Merck biologics plant in U.K. News

> DSM sets June launch for Australian biologics plant. Article

Biotech Research News

 @EmilyMFierce: Intel, Oregon Health & Science University partner on genetic profiling project. More | Follow @EmilyMFierce

> Antibody genes linked to ethnicity. Item

> Autistic behavior has genetic basis in mice. Article

> Radioactive bacteria treatment stops metastasis in mice. More

> Columbia researchers identify hundreds of potential metabolic cancer targets. Story

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.